Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028287 · ClinicalTrials.gov registry record · Phase 4
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
A Phase 4 study of Diabetic Nephropathy and Nephrotic Syndrome, sponsored by Southeast Renal Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01028287: Completed Phase 4 study of Diabetic Nephropathy and Nephrotic Syndrome, sponsored by Southeast Renal Research Institute.
NCT01028287 is a Phase 4 study of Diabetic Nephropathy and Nephrotic Syndrome that has completed, run by Southeast Renal Research Institute. The registered enrollment target is 15 participants, below the 11,429-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01028287, a Phase 4 study of Diabetic Nephropathy and Nephrotic Syndrome, has completed, sponsored by Southeast Renal Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective open labeled trial examining the efficacy of ACTHar Gel (porcine ACTH) on the level of proteinuria in patients with diabetic nephropathy and nephrotic range proteinuria.
Conditions Studied
Interventions
- DRUG ACTH
Study Locations (1)
Tennessee
- Southeast Renal Research Institute - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
What the finished NCT01028287 record still lists
NCT01028287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 11,429-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Diabetic Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which ACTH is the first listed.
NCT01028287 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01028287 about?
NCT01028287 is a clinical study titled "Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)". This is a prospective open labeled trial examining the efficacy of ACTHar Gel (porcine ACTH) on the level of proteinuria in patients with diabetic nephropathy and nephrotic range proteinuria.
What is the current status of trial NCT01028287?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2009-05. Estimated completion is 2011-07.
What conditions does trial NCT01028287 study?
This clinical trial studies the following conditions: Diabetic Nephropathy, Nephrotic Syndrome.
What interventions are being tested in trial NCT01028287?
The interventions under investigation include: ACTH (DRUG).
Who is sponsoring clinical trial NCT01028287?
This trial is sponsored by Southeast Renal Research Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01028287 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01028287's enrollment target sits among peer trials
15 10th of 9 the lowest of 9 other Diabetic Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RECRUITING
-
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
COMPLETED · Phase 2
-
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
COMPLETED · NA
-
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia